Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by G1945Von Jan 22, 2023 11:27am
143 Views
Post# 35238449

RE:Communication with MTP Stockholders

RE:Communication with MTP Stockholders
G1945V wrote: Is there any ongoing communication with Midatech Pharma PLC shareholders on any forum?  

G1945V


I guess the reason why there is a lack of communication on the part of Midatech (MTP) shareholders is that the general public only holds ~12% of the total outstanding shares.

Institutional investors hold ~68%. Private companies hold ~10%. Hedge Funds hold ~7%. I guess the vote tomorrow to merge with BTI will pass with flying colours.

MTP Reverse split of September 26, 2022. :

https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2022-253


"Midatech Pharma PLC (MTP) will affect a one-for-five (1-5) reverse split of its American Depositary Shares (“ADS”), and a ratio change from one ADS representing five Ordinary Shares (1:5) to one ADS representing twenty-five Ordinary Shares (1:25). The reverse stock split will become effective on Monday, September 26, 2022. In conjunction with the reverse split, the CUSIP number will change to 59564R500"

The rest hinges on BTI's general public shareholders, for the merger to take place, holding ~98% of the outstanding shares.

GLTA
G1945V


<< Previous
Bullboard Posts
Next >>